Therapeutic Efficacy of Aldoxorubicin in an Intracranial Xenograft Mouse Model of Human Glioblastoma

Therapeutic Efficacy of Aldoxorubicin in an Intracranial Xenograft Mouse Model of Human Glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with a median survival of 12 to 15 months after diagnosis. Acquired chemoresistance, high systemic toxicity, and low penetration of the blood brain barrier by many anticancer drugs contribute to the failure of anti-GBM therapi...

Full description

Bibliographic Details
Main Authors: Luis Marrero, Dorota Wyczechowska, Alberto E. Musto, Anna Wilk, Himanshu Vashistha, Adriana Zapata, Chelsey Walker, Cruz Velasco-Gonzalez, Christopher Parsons, Scott Wieland, Daniel Levitt, Krzysztof Reiss, Om Prakash
Format: Article
Language:English
Published: Elsevier 2014-10-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558614001213

Internet

http://www.sciencedirect.com/science/article/pii/S1476558614001213

Similar Items